Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Semaglutide is an anti-diabetic medication used for the treatment of type 2 diabetes, and an anti-obesity medication used for weight management. It can be administered by subcutaneous injection or taken orally . It is sold as a generic drug by several drug companies in the Indian and Canadian markets, and worldwide by its originator, Novo Nordisk, under the brand names Ozempic and Rybelsus for diabetes; under the brand name Wegovy for weight management; and under the brand names Wegovy and Kayshild for the treatment of metabolic-associated steatohepatitis (nonalcoholic steatohepatitis) and liver cirrhosis. Wegovy is also used to reduce the risk of heart attacks.
Read the full article on WikipediaDiabetes mellitus type 2 Clinical criteria: Treatment Phase: First PBS-prescription for this drug The treatment must be used in combination with at least one of: metformin, a sulfonylurea, insulin, AND The condition must be inadequately responsive to at least one of: metformin, a sulfonylurea, insulin, AND Patient must not have achieved a clinically meaningful glycaemic response with an SGLT2 inhibitor; OR Patient must have a contraindication/intolerance requiring treatment discontinuation of an SGLT2 inhibitor. Treatment criteria: Patient must not be undergoing concomitant PBS-subsidised treatment for type 2 diabetes mellitus with any of: an SGLT2 inhibitor, a DPP4 inhibitor, another GLP-1 receptor agonist.
“Semaglutide is a glucagon-like peptide-1 receptor agonist. The drug decreases mimicks the hormone glucagon-like peptide-1 (GLP-1), an incretin. This produces a myriad of effects on metabolism pathways:”
“7 days”
Working under the parallel aged-care framework? Aged-care equivalent →